<DOC>
	<DOCNO>NCT02337322</DOCNO>
	<brief_summary>There randomize clinical trial advance HIV patient . This multicenter , randomize , open clinical trial , compare 2 parallel group , compare immunological reconstitution virological efficacy safety 2 different combination antiretroviral therapy give day ( QD ) : abacavir plus lamivudine plus either dolutegravir , darunavir-ritonavir 96 week advance antiretroviral naïve HIV-1 infect patient less 100 CD4+ T-cells/mm3 . Primary endpoint median increase CD4+ T-cell count 48 week start HAART .</brief_summary>
	<brief_title>Immune Recovery Advanced , ARV-naïve , HIV-1-infected Individuals Taking Dolutegravir Ritonavir-boosted Darunavir</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>1 . HIV patient &gt; 18 year old provide sign date informed consent . 2 . Male female . 3 . Chronic HIV infection . 4 . Antiretroviral naïve . 5 . Confirmed CD4+ T cell count 100 cells/mm3 6 . HLA B5701 negative patient . 1 . Active opportunistic infection require parenteral treatment 2 . Patients cryptococcal meningitis treat voriconazole 3 . AIDSdefining cancer need chemotherapy . 4 . Female patient pregnant breastfeeding . 5 . Patients document history allergy sulfonamide . 6 . Any contraindication study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Acquired Immune Deficiency Syndrome Virus</keyword>
	<keyword>HIV</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Antiretroviral treatment</keyword>
	<keyword>HIV Advanced Disease</keyword>
	<keyword>AIDS</keyword>
	<keyword>Dolutegravir</keyword>
	<keyword>Darunavir</keyword>
</DOC>